An Open Label Study to Examine the Effects of Low-Fat and High-Fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients.
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 21 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2009 Additional location South Korea identified as reported by ClinicalTrials.gov, last updated 5-Mar-09.
- 05 Mar 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.